How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,770 results for

Cerebral Aneurysm

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5361. Behavioral and Functional MRI Task Development, Implementation, and Testing

, 2019 See Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute on Alcohol Abuse and Alcoholism (NIAAA) ) Study Details Study Description Go to Brief Summary: Background: - Scientists know that alcohol use disorders affect brain structure. They want to know more about the effects of alcohol use disorders on a person s behavior. They want to develop tasks that can be done (...) blood and urine samples and have a psychiatric interview. Participants will have between one and three visits. Participants will be asked about their alcohol drinking to see if they have an alcohol use disorder. Participants will complete one of three simple computerized tasks either inside the magnetic resonance imagining (MRI) scanner or outside of it. The MRI scanner takes pictures of the brain. The scanner is a metal cylinder. Participants lie on a table that can slide in and out of the cylinder

2014 Clinical Trials

5362. Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct

as defined in TROFI I, measured by OCT Secondary Outcome Measures : Total Death [ Time Frame: 5 years ] Total death encompasses cardiac death and other fatal categories, which include cerebrovascular death, death from other cardiovascular disease (i.e. pulmonary embolism, dissection aortic aneurysm will be included in this category), death from malignant disease, death from suicide, violence or accident, or death from other reasons. Cardiac death [ Time Frame: 5 years ] Cardiac death encompasses coronary (...) : 5 years ] Coronary artery bypass grafting with grafting or PCI of index lesion. Coronary artery bypass grafting with grafting or PCI of index vessel. Non Target vessel revascularisation [ Time Frame: 5 years ] All PCI or coronary bypass grafting of non index vessel Stable angina [ Time Frame: 5 years ] Angina as reported by patient, classified according to Canadian cardiac society class (CCS) Vascular cerebral events [ Time Frame: 5 years ] Vascular events documented by neurological permanent

2014 Clinical Trials

5363. Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection

participants will undergo a standardized routine MRI scan of brain and neck before study entry. 14 +/- 7 days after treatment onset a second MRI of brain and neck will be performed. The following MRI sequences will be performed on a 3 Tesla scanner (1) spin echo (SE) T1w, turbo spin-echo (TSE) T2w, FLAIR to detect chronic ischemic brain lesions. (2) Diffusion weighted imaging (DWI) including apparent diffusion coefficient (ADC) maps to detect acute ischemic brain lesions. (3) susceptibility-weighted (...) imaging (SWI) sequences or T2*w gradient echo (GRE) to detect hemorrhagic brain lesions (4) contrast-enhanced magnetic resonance angiography (CE-MRA) to improve delineation of the wall hematoma against the perfused vessel lumen, and to assess the degree of obstruction of the affected artery. MRI scans will be centrally analysed at the University Hospital Basel, and independently assessed by two observers who are blinded to the type of treatment and clinical outcome. Clinical examination: Patients

2014 Clinical Trials

5364. Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

or infratentorial tumor Evidence or suspicion of disease metastatic to sites remote from supratentorial brain Prior treatment with anti-vascular endothelial growth factor (VEGF) drugs other than bevacizumab Prior treatment with tyrosine-kinase inhibitors targeting VEGF, platelet-derived growth factor, fibroblast growth factor, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (TIE-2), or angiopoietin (or their receptors) Prior treatment with histone deacetylase inhibitors (...) (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation) Grade 2 or higher peripheral neuropathy per NCI CTCAE History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 Serious, non-healing wound

2014 Clinical Trials

5365. Microvascular Disease Exercise Trial

: Prior CABG (due to limitations of CMR quantitative perfusion in this population) Prior myocardial infarction (due to its effects on myocardial flow reserve) Hypertrophic or restrictive cardiomyopathy Coronary vasospasm Acute coronary syndrome unless concurrent coronary angiography reveals no epicardial stenoses of >50% Contraindications to CMR including - intracranial aneurysm clips, implantable pacemaker or defibrillator, metal cochlear/intraocular implants, any metallic implant not listed

2014 Clinical Trials

5366. Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of: Hemorrhagic disorders or bleeding diathesis Occult blood in faeces or haematuria Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation History of arteriovenous malformation or aneurysm History of gastroduodenal ulcer disease or gastrointestinal haemorrhage History of intracranial, intraocular, spinal

2014 Clinical Trials

5367. MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression

of Arkansas Information provided by (Responsible Party): University of Arkansas Study Details Study Description Go to Brief Summary: The purpose of this study is to (a) measure how brain structure, metabolism (how the brain uses energy), and function predict response to electroconvulsive therapy (ECT) for treatment of depression; and (b) measure how ECT changes brain metabolism and function. We will ask you to undergo magnetic resonance imaging (MRI) at three sessions: (1) prior to your first ECT therapy (...) ) Exclusion Criteria: Claustrophobia, or the inability to lie still in a confined space Magnetic metallic implants (such as screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents), as these may heat, pull, or twist in the strong magnetic field of the MRI scanner Electronic or magnetic implants, such as pacemakers, as these may stop working Non-removable dental implants, such as braces or permanent retainers

2014 Clinical Trials

5368. CNS Uptake of Intranasal Glutathione

or more of the required positive criteria for PD from Step 3 of the UK Brain Bank Diagnostic Criteria for Parkinson's Disease. A modified Hoehn & Yahr Stage 2-3. (bilateral disease, not severely disabled.) Exclusion Criteria: Any contra-indication to magnetic resonance imaging, including pacemaker, pacemaker wires, aneurysm clip, or any electronic implant, weight over 136 kg (300 lb), metal embedded in soft tissue or in the eye, prosthetic eye, claustrophobia, substance abuse, use of recreational (...) Study Details Study Description Go to Brief Summary: Excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility

2014 Clinical Trials

5369. Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes

the use of any assistive devices (e.g. cane, walker, or wheelchair). Exclusion Criteria: Left handedness Presence of a clip to repair a cerebral aneurysm (broken blood vessel in the head), cardiac pace-maker, cochlear implants (internal hearing aids) or metal fragments or pieces in eyes or any other part of body. Non MRI compatible metal in any part of body. Physician's instruction that it is medically unsafe for subject to receive regular MRI as part of their medical care. Engagement (...) in the professions of painting or welding or other occupation that precludes an individual from getting a regular MRI. Proneness to claustrophobia (fear of enclosed spaces), to my knowledge. History of schizophrenia or bipolar disorder. Pregnancy History of stroke, brain Injury or neurological disease other than MS. Evidence of a flare up of MS symptoms within the past month. Administration of the following in last month: steroids, benzodiazepines, neuroleptics or opiates, as determined by the study doctor

2014 Clinical Trials

5370. Clinical Implications of DNA Analysis on ADPKD

method. Other Outcome Measures: The relationship between mutational types and phenotypes; [ Time Frame: One year. ] • The radiologic findings of intracranial aneurysm and cerebral arteries. Biospecimen Retention: Samples With DNA Blood Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you

2014 Clinical Trials

5371. Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease

Phase. Participants with significant pathological findings on brain MRI including but not limited to: an area of superficial siderosis; evidence of cerebral vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas (...) , 2014 Last Update Posted: March 4, 2019 Last Verified: June 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Keywords provided by Eisai Inc.: E2609 Mild Cognitive Impairment Mild to Moderate Dementia Alzheimer's Disease Prodromal Alzheimer's Disease Additional relevant MeSH terms: Layout table for MeSH terms Alzheimer Disease Dementia Cognitive Dysfunction Brain Diseases

2014 Clinical Trials

5372. MicroRNA Diagnostics in Subarachnoid Hemorrhage 2

Go to Brief Summary: The purpose of this study is to validate results from a related trial (NCT01791257) and to compare the profile of microRNA in blood from patients suffering subarachnoid hemorrhage with and without systemic complications. Condition or disease Subarachnoid Hemorrhage Delayed Cerebral Ischemia Acute Lung Injury Cardiac Dysfunction Systemic Inflammatory Response Syndrome Detailed Description: In this study of patients suffering an aneurysmal subarachnoid hemorrhage (SAH) we would (...) on the Glasgow Coma Scale (either on the total score or on one of its individual components [eye, motor on either side, verbal]). This should last for at least 1 hour, is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or MRI scanning of the brain, and appropriate laboratory studies." Systemic complications: Furthermore, we wish to compare the expression of 754 specific microRNA in blood drawn on day 3 after ictus between

2014 Clinical Trials

5373. The Adult Hemorrhagic Moyamoya Surgery Study

for follow-up Exclusion Criteria: Other cerebrovascular diseases(such as intracranial aneurysm or brain arteriovenous malformation) probably causing intracranial hemorrhage Not independent in activity of daily living(The modified Rankin Scale 3-5) Moyamoya syndrome concomitant with other hereditary or autoimmune diseases(Grave's Disease,Type I Diabetes Mellitus,Type I Neurofibromatosis et al) Moyamoya disease with ruptured aneurysms located in the main stem of Willis' Circle Emergent evacuation (...) Party: Hanqiang Jiang,MD, PhD, Huashan Hospital Identifier: Other Study ID Numbers: CAHMD 2014 First Posted: December 19, 2014 Last Update Posted: February 17, 2016 Last Verified: February 2016 Additional relevant MeSH terms: Layout table for MeSH terms Moyamoya Disease Carotid Artery Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Cerebral Arterial Diseases Intracranial Arterial Diseases Arterial Occlusive Diseases

2014 Clinical Trials

5374. Vibration Training and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence

implants Acute arthritis Osteoporosis with vertebral fracture Recent Fracture Acute Soft Tissue Injury Acute Rheumatoid Arthritis Cardiovascular Recent myocardial infarction Hypertension Serious cardiovascular disease Artificial heart valves Pacemaker Venous Thrombosis Aortic Aneurysm Peripheral vascular disease Untreated orthostatic hypotension Hernia Neuromuscular Impaired sensation Impaired cognition Deep brain and spinal cord stimulators Other Malignant tumours Acute oedema Impaired skin integrity

2014 Clinical Trials

5375. Perioperative Neuroprotection of Stellate Ganglion Block

Hospital of Ningxia Medical University Information provided by (Responsible Party): General Hospital of Ningxia Medical University Study Details Study Description Go to Brief Summary: To investigate whether stellate ganglion block is helpful to brain protection during cranial aneurysm surgery Condition or disease Intervention/treatment Phase Intracranial Aneurysm Drug: Stellate Ganglion Block Not Applicable Detailed Description: The vasospasm after cranial aneurysm surgery have a higher incidence (...) table for MeSH terms Aneurysm Intracranial Aneurysm Ganglion Cysts Vasospasm, Intracranial Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Cysts Neoplasms Mucinoses Connective Tissue Diseases Ropivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents

2014 Clinical Trials

5376. Oxytocin Effects on Food Motivation Pathways

Description Go to Brief Summary: Oxytocin is a peptide hormone produced in the brain that regulates food intake. However, the mechanisms for this effect in humans is not yet clear. In this study, the investigators will therefore examine the effect of a single dose of intranasal oxytocin (compared to placebo) on levels of appetite-regulating hormones and functional magnetic resonance imaging activation of areas of the brain involved in food motivation. Condition or disease Intervention/treatment Phase (...) Date : May 2015 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Oxytocin Oxytocin 24 IU x 1 Drug: Oxytocin Single dose, intranasal Other Name: Syntocinon Placebo Comparator: Placebo Placebo 24 IU x 1 Drug: Placebo Single dose, intranasal Outcome Measures Go to Primary Outcome Measures : Change in functional magnetic resonance imaging activation of food motivation brain regions [ Time Frame: Functional

2014 Clinical Trials

5377. The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity

Macular Degeneration Presence or history of Glaucoma Presence or history of Diabetes Mellitus Any Retinal pathology - retinal detachment, retinitis pigmentosa, diabetic retinopathy, etc Vision loss due to Central retinal artery occlusion or Central retinal vein occlusion Vision loss due to presence of large pituitary tumors or aneurysms Vision loss due to optic tract lesions Vision loss due to bleeding into aqueous or vitreous chamber Vision loss due to drug toxicity: Amiodarone, anti-tuberculosis (...) drugs, hydroxychloroquine, tamoxifen Major cardiovascular or cerebral events in the past 12 months Allergy to fish oil or safflower oil Pregnancy or lactation at any time during the study Newly started or increased the dose of chronic systemic medication known to affect tear production including, but not limited to antihistamines, antidepressants, diuretics, corticosteroids or immunomodulators within 30 days of Screening or at any time during the study Participation in any other study involving

2014 Clinical Trials

5378. Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual

(such as antisocial, schizotypal, histrionic, borderline, narcissistic) as assessed by the investigator to be primary, causing a higher degree of distress or impairment than MDD. Patients who have conductive, ferromagnetic or other magnetic- sensitive metals implanted in their head or within 30 cm of the treatment coil. Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes Patients who have active or inactive implants (...) (including device leads), including cardiac pacemakers, implanted defibrillators, deep brain stimulators, cochlear implants, and vagus nerve stimulators Known or suspected pregnancy Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse Minimal MT found for both hands is higher than 70% of stimulator power output Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2014 Clinical Trials

5379. A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

disease ischemic stroke or transient ischemic attack (TIA) intracranial hemorrhage History of abdominal aortic aneurysm. Participants with a history of intolerance/hypersensitivity to ezetimibe or statins. Have systolic blood pressure (SBP) > 160 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) > 100 mm Hg. Have a hemoglobin A1c ≥8.4% (National Glycohemoglobin Standardization Program). During the study period, participants who plan to use, are likely to require, or unwilling or unable

2014 Clinical Trials

5380. A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

ischemic attack (TIA) intracranial hemorrhage abdominal aortic aneurysm Have systolic blood pressure (SBP) >160 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) >100 mm Hg. Have a hemoglobin A1c ≥8.4% (National Glycohemoglobin Standardization Program). During the study period, participants who plan to use, are likely to require, or unwilling or unable to stop with adequate washout any prescription, over the counter medication, supplements or health foods with the intent to treat serum

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>